Icon (NASDAQ:ICLR) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $6.69-6.89 for the period, compared to the Thomson Reuters consensus estimate of $6.81. The company issued revenue guidance of $2.735 – $2.835 billion, compared to the consensus revenue estimate of $2.78 billion.
Several research firms have recently issued reports on ICLR. BidaskClub upgraded shares of Icon from a buy rating to a strong-buy rating in a report on Saturday, December 1st. Zacks Investment Research lowered shares of Icon from a hold rating to a sell rating in a report on Wednesday, October 24th. UBS Group set a $136.00 target price on shares of Icon and gave the stock a sell rating in a report on Saturday, October 27th. Goldman Sachs Group lowered shares of Icon from a conviction-buy rating to a buy rating and set a $168.00 target price for the company. in a report on Friday, December 14th. Finally, Evercore ISI raised shares of Icon from an in-line rating to an outperform rating in a research note on Friday, October 26th. Two investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $153.11.
ICLR stock traded up $0.64 during trading on Wednesday, hitting $145.92. The company had a trading volume of 241,600 shares, compared to its average volume of 270,700. The company has a market capitalization of $7.84 billion, a PE ratio of 27.07, a P/E/G ratio of 1.82 and a beta of 0.71. Icon has a 52-week low of $110.21 and a 52-week high of $155.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17.
ILLEGAL ACTIVITY WARNING: “Icon (ICLR) Releases FY19 Earnings Guidance” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.themarketsdaily.com/2019/02/21/icon-iclr-releases-fy19-earnings-guidance-2.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also: Front-End Load
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.